---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-000762"
form_type: "8-K"
ticker: "FHTX"
cik: "0001822462"
company_name: "Foghorn Therapeutics Inc."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:32:12.876574+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Foghorn outlines 2024 pipeline milestones; AML combo data expected H2, six INDs over four years

## Summary
- FHD-286 Phase 1 combination study in AML continues; first data expected H2 2024.
- Preclinical combo data with TKIs in EGFR/KRAS resistance expected Q2 2024.
- Selective EP300 and CBP degraders show efficacy without thrombocytopenia; CBP IND enabling studies targeted before end of 2024.
- At least six new INDs planned over next four years across >20 tumor types.
- Cash $259.9M as of Sep 30, 2023; runway into H1 2026.

## SEC filing metadata
- accession: 0001628280-24-000762
- form_type: 8-K
- ticker: FHTX
- cik: 0001822462
- company_name: Foghorn Therapeutics Inc.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822462/000162828024000762/0001628280-24-000762-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822462/000162828024000762/fhtx-20240108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-000762
- JSON: https://secwatch.observer/filing/0001628280-24-000762.json
- Plain text: https://secwatch.observer/filing/0001628280-24-000762.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.